17 Current news of Abbott


You can refine your search further. Select from the filter options on the left to narrow down your results.

Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus

Company scaling up production at its U.S. manufacturing location


Abbott announced that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company's molecular test for novel coronavirus (COVID-19). Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. The tests are ...


Abbott acquisition of St. Jude Medical set to close


Abbott announced it intends to close the acquisition of St. Jude Medical, Inc. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction establishes Abbott as a leader in the medical device arena and provides expanded opportunities for future growth. The ...


Abbott Receives CE Mark for New Hepatitis Test

New Highly Sensitive Hepatitis Test Detects Mutant Virus Strains


Abbott announced it has received CE Marking (Conformité Européenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg). The test is performed on Abbott's ARCHITECT® system. HBsAg assays may be used to help identify acute ...


Abbott Introduces New ALK Genetic Test for Specific Form of Non-Small-Cell Lung Cancer


Abbott announced the availability of a new molecular test in the European Union and New Zealand designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung cancer (NSCLC). These rearrangements in a gene known as ALK (anaplastic lymphoma kinase) ...


Abbott's New HIV-1 Qualitative Assay Improves Testing Access in Remote Areas for Children and Adults


Abbott announced that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to ...


QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV


QIAGEN and Abbott announced that they have entered into an agreement that significantly strengthens both companies’ testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed. Under the terms of the agreements, QIAGEN will ...


Abbott Completes Acquisition of STARLIMS Technologies


Abbott announced that it has completed its $123 million acquisition of STARLIMS Technologies Ltd. The acquisition provides Abbott with products and expertise to build its position in laboratory informatics "STARLIMS gives us access to innovative technologies and technical expertise for our ...


Abbott Completes Acquisition of Advanced Medical Optics


Abbott announced that it has completed its acquisition of Advanced Medical Optics. AMO is now a wholly owned subsidiary of Abbott and has been renamed Abbott Medical Optics Inc. The acquisition of AMO enhances and strengthens Abbott's diverse mix of medical device businesses and gives it a ...


Internationale Vereinigung für Klinische Chemie schliesst sich der "Labs Are Vital(TM)"-Initiative an

Betonung der entscheidenden Rolle von Laborfachkräften und Erörterung der Probleme von klinischen Labors weltweit


Aus aller Welt kommen Fachkräfte aus dem klinischen Laborbereich zur Unterstützung einer Initiative zusammen, die das internationale Bewusstsein für die Rolle, die klinische Laborfachkräfte im Gesundheitswesen spielen, sensibilisieren und betonen will, welchen entscheidenden Beitrag sie für das ...


Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response

Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer


Abbott announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) (erlotinib), an oral tablet indicated for the ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE